JP2021167329A5 - - Google Patents

Download PDF

Info

Publication number
JP2021167329A5
JP2021167329A5 JP2021109873A JP2021109873A JP2021167329A5 JP 2021167329 A5 JP2021167329 A5 JP 2021167329A5 JP 2021109873 A JP2021109873 A JP 2021109873A JP 2021109873 A JP2021109873 A JP 2021109873A JP 2021167329 A5 JP2021167329 A5 JP 2021167329A5
Authority
JP
Japan
Prior art keywords
protein
cell
nucleic acid
permeable
phosphorothioate nucleic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021109873A
Other languages
English (en)
Japanese (ja)
Other versions
JP7260596B2 (ja
JP2021167329A (ja
Filing date
Publication date
Priority claimed from JP2018506182A external-priority patent/JP7104462B2/ja
Application filed filed Critical
Publication of JP2021167329A publication Critical patent/JP2021167329A/ja
Publication of JP2021167329A5 publication Critical patent/JP2021167329A5/ja
Application granted granted Critical
Publication of JP7260596B2 publication Critical patent/JP7260596B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021109873A 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法 Active JP7260596B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562202006P 2015-08-06 2015-08-06
US62/202,006 2015-08-06
JP2018506182A JP7104462B2 (ja) 2015-08-06 2016-08-05 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018506182A Division JP7104462B2 (ja) 2015-08-06 2016-08-05 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Publications (3)

Publication Number Publication Date
JP2021167329A JP2021167329A (ja) 2021-10-21
JP2021167329A5 true JP2021167329A5 (https=) 2021-12-09
JP7260596B2 JP7260596B2 (ja) 2023-04-18

Family

ID=57943680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018506182A Active JP7104462B2 (ja) 2015-08-06 2016-08-05 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法
JP2021109873A Active JP7260596B2 (ja) 2015-08-06 2021-07-01 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018506182A Active JP7104462B2 (ja) 2015-08-06 2016-08-05 細胞透過性タンパク質-抗体コンジュゲートおよび使用方法

Country Status (7)

Country Link
US (2) US11661463B2 (https=)
EP (1) EP3331543A4 (https=)
JP (2) JP7104462B2 (https=)
CN (2) CN108135958B (https=)
AR (1) AR105642A1 (https=)
TW (1) TW201718023A (https=)
WO (1) WO2017024238A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3331543A4 (en) * 2015-08-06 2019-03-20 City of Hope Cell-pollenizing protein antibody conjugates and methods of use
CN108866635B (zh) * 2017-05-09 2021-11-26 安升(上海)医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
JP7295838B2 (ja) * 2017-07-13 2023-06-21 シティ・オブ・ホープ ホスホロチオエートコンジュゲートペプチド及びその使用方法
EP3730150A4 (en) * 2017-12-22 2021-10-06 Rophibio, Inc. ANTI-STAT3 BISPECIFIC ANTIBODY WITH CELL-PENETRATING ABILITY AND THIS PHARMACEUTICAL COMPOSITION
KR102526768B1 (ko) * 2017-12-22 2023-04-27 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체
KR102256985B1 (ko) 2019-06-25 2021-06-03 주식회사 로피바이오 항 stat3 특이 항체 및 이를 포함하는 약학적 조성물
EP4153762A4 (en) * 2020-05-22 2025-05-07 City of Hope Phosphorothioate nucleic acid conjugates with DNA-editing enzymes
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
EP4634373A1 (en) 2022-12-16 2025-10-22 University of Rochester Repairment of barrier dysfunction in esophagus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992000373A1 (en) 1990-06-29 1992-01-09 Biosource Genetics Corporation Melanin production by transformed microorganisms
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
AU2006325030B2 (en) 2005-12-16 2012-07-26 Cellectis Cell penetrating peptide conjugates for delivering nucleic acids into cells
US20100239504A1 (en) * 2007-07-17 2010-09-23 The General Hospital Corporation Imaging nucleic acid binding proteins
EP2090584A1 (en) 2008-02-13 2009-08-19 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Identification of a novel cysteine-rich cell penetrating peptide
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
JP2013541510A (ja) 2010-08-31 2013-11-14 メルク・シャープ・エンド・ドーム・コーポレイション 新規の単一の化学物質、およびオリゴヌクレオチドの送達方法
WO2013101690A1 (en) 2011-12-29 2013-07-04 modeRNA Therapeutics Modified mrnas encoding cell-penetrating polypeptides
KR101567576B1 (ko) * 2012-05-22 2015-11-10 올릭스 주식회사 세포 내 관통능을 가지고 rna 간섭을 유도하는 핵산 분자 및 그 용도
CN105658230B (zh) * 2013-08-29 2020-04-21 希望之城 细胞穿透缀合物及其使用方法
UY36519A (es) 2015-01-16 2016-08-31 Hope City Anticuerpos de penetración celular
EP3331543A4 (en) * 2015-08-06 2019-03-20 City of Hope Cell-pollenizing protein antibody conjugates and methods of use

Similar Documents

Publication Publication Date Title
JP2021167329A5 (https=)
JP2018525381A5 (https=)
JP2021502810A5 (https=)
Boersma et al. DARPins and other repeat protein scaffolds: advances in engineering and applications
US7138105B2 (en) Compositions for delivery of therapeutics and other materials, and methods of making and using the same
Lee et al. Therapeutic aptamers: developmental potential as anticancer drugs
JP2021531826A5 (https=)
JP2021152022A5 (https=)
R Kanwar et al. Nucleic acid-based aptamers: applications, development and clinical trials
JP2021524275A5 (https=)
JP2018525001A5 (https=)
JP2019522490A5 (https=)
JP2021524270A5 (https=)
JP2011530537A5 (https=)
JP2019513692A (ja) 核酸キャリア及び治療上の使用方法
JP2010515678A (ja) キトサン基材高分子接合体及びその製造方法
JP2013513377A5 (https=)
JP2018505870A5 (https=)
WO2017205277A2 (en) Methods for using nucleic acid aptamers for directed templated assembly
Liu et al. Nanoparticle delivery: targeting and nonspecific binding
JP2023515708A5 (https=)
JP5991535B2 (ja) アミロイドタンパク質オリゴマー結合アプタマー
JP2018512858A (ja) 癌治療のためのヒト抗原R発現のsiRNA阻害
JP2011523849A5 (https=)
JP2023548590A5 (https=)